Featured series: Recent development in cancer immunotherapy
Due to recent technological and scientific advancements, the past few years have seen dramatic breakthroughs in the burgeoning field of immunotherapy. These and future advances in immunotherapy have the potential to transform cancer treatment and the lives of patients. This thematic series, published in the Journal of Hematology & Oncology, covers some of the recent advances in cancer immunotherapy.
Aims and scope
Journal of Hematology & Oncology is an open access, peer-reviewed online journal that encompasses all aspects of hematology and oncology.
Experimental Hematology & Oncology
Submit your research to our companion journal, Experimental Hematology & Oncology
"Journal of Hematology & Oncology provides a forum for top-quality research and is a leading title in hematology and oncology, with an Impact Factor ranked in Q1 in both categories. The journal also publishes reviews and research highlights from leading experts in the field. Research is shared with fast turnaround times in an open access format among laboratory scientists, physician scientists, hematologists and oncologists."
Prof Delong Liu, Editor-in-Chief, Journal of Hematology & Oncology
Journal of Hematology & Oncology is now publishing Research Highlights, commentaries on recently published work that place the new research in the context of the current literature.
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu
Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting—its impact on clinical practice
Gaurav Goel, Weijing Sun